Tag: Vaccine

Partnership expands the Wisconsin Idea by providing interdisciplinary collaborations with UW-Madison, the Ella Foundation, and Bharat Biotech

According to GlobalData’s Pharma Intelligence Center, there are currently 19 COVID-19 vaccines in clinical development in China, with only 3 candidates in Phase III trials

The agreement was signed on 27 December 2022 at the office of Agrinnovate India, New Delhi

As per AIG study, protein-based vaccine when given as a booster shown to induce not only increased antibody response but also robust T-cell and B-cell (memory cell) response linked with long-term immunity

Effective dengue prevention requires a multi-faceted approach, and previous methods have been insufficient for a number of reasons

While efforts are still on to uncover findings about the COVID-19 and the epidemiological models, India is ready to invest in future challenges

Randomized, double blinded, placebo-controlled trial. Evaluation of two doses in 36 volunteers. Mid-term data expected by end Q1 2023

TAK-003 is being evaluated for the prevention of dengue disease caused by any dengue virus serotype in individuals 4 years through 60 years of age

Drone delivery of vaccines is expected to not only reach remote difficult terrains faster but also help in providing critical vaccines on time

CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus